Wednesday 4.3.2020

Colposcopy precourse Organized by local organizer

Afternoon/evening: meetings CTU-Foundation Board (prior or after evening symposium?), NSGO Board (prior of after evening symposium?)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.00 – 18.30</td>
<td>Buffet</td>
</tr>
</tbody>
</table>
| 18.30 – 20.30 | **NSGO Symposium: Immuno-Oncology in Gynaecological cancers**  
                 Chairs: Mansoor Mirza and Line Bjørge |
| 18.30 – 18.50 | Lana Kandalaft: an overview               |
| 18.50 – 19.10 | Ana Oaknin: IO in cervical cancer        |
| 19.10 – 19.30 | Mansoor Raza Mirza: IO in endometrial cancer |
| 19.30 – 19.50 | Jonathan Ledermann: IO in ovarian cancer  |
| 19.50 – 20.30 | Discussion                               |
NSGO Annual Meeting 2020
Radisson Blu Airport Hotel, Oslo Gardermoen
Hotellvegen, 2060 Gardermoen, Norway

Theme:
Prevention and heredity in cancer
4 – 6 March 2020

This meeting will be sponsored by several medical companies
Thursday 5.3.2020

08.00 – 09.30 NSGO-CTU Scientific committee Meeting (closed)
08.00 – 09.30 Other WG:s, such as Surgery Group, Radiotherapy Group, Quality WG. WG chairmen will call the meetings

09.30 – 10.00 Registration

10.00 – 10.10 Opening of the Annual Meeting / NSGO President

10.10 – 12.30 SESSION: Preventing gynecological cancers
Chairs: Line Bjørge and Isa Niemann

10.15 – 10.45 Joakim Dillner: Prospects for elimination of cervical cancer
10.45 – 11.15 Emma Crosbie: Prevention of endometrial cancer
11.15 – 11.45 Martin Widschwendter: Epigenome –based risk prediction of gynecological cancers
11.45 – 12.15 Discussion

12.15 – 14.00 Exhibition and Lunch (13-14)

14.00 – 16.00 Investigator meeting
Chair: Mansoor Mirza

16.00 – 17.00 3MThesis competition with refreshments

17.00 – 17.30 Coffee break and exhibition

17.30 – 19.00 NSGO Symposium: PARP-inhibitors treatment in ovarian cancer
Chairs: Mansoor Mirza and Annika Auranen

17.30 – 17.50 Ian McNeish: The molecular landscape of ovarian cancer
17.50 – 18.10 Robert Coleman: PARP-inhibitors at frontline treatment of ovarian cancer
18.10 – 18.30 Mansoor Mirza: PARP-inhibitors at recurrence of ovarian cancer
18.30 – 19.00 Discussion

20.00 Welcome drink

20.30 – Dinner
Friday 6.3.2020

08.00 – 09.00 General Assembly (closed)

09.00 – 11.30 SESSION: How has knowledge of genetics and heredity impacted treatment of gynecological cancers?
Chairs: Annika Auranen and Gabriel Lindahl

09.05 – 09.35 Þórunn Rafnar: BRCA1 and BRCA2 and BRCA related mutations, where do we stand

09.35 – 10.15 Panel discussion with Nordic representatives + Emma Crosbie and Susana Banerjee

- What are the testing procedures in different Nordic countries for OVCA patients
- What are the findings? Founder mutations? VUS? etc
- Other questions regarding BRCA testing (cascade testing, cost eff. etc)
- Risk-reducing strategies / guidelines used

10.15 – 11.00 Susana Banerjee: Ovca treatment options based on molecular classification/BRCAmut/HRD

11.00 – 11.30 Discussion

11.30 – 12.30 Lunch

12.30 – 14.45 SESSION: How has knowledge of genetics and heredity impacted treatment of gynecological cancers? continued
Chairs: Päivi Kannisto and Ben Davidson

12.30 – 13.00 Toni Seppälä: Lynch syndrome and EC
13.00 – 13.30 Ben Davidson: Endometriosis-associated neoplasia
13.30 – 14.00 Hanny Pijnenborg: Personalized therapy for EC
14.00 – 14.30 Discussion